Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Medicare Bill Directs GAO To Study International Price Controls

Executive Summary

The Senate Medicare legislation would direct the General Accounting Office to produce a study of international price controls within one year of enactment

You may also be interested in...



Medicare Law Puts Rx In Spotlight Of Presidential Campaign Politics

Restrictions on direct-to-consumer advertising of prescription drugs are among health care proposals being offered by 2004 Democratic presidential candidates

Medicare Law Puts Rx In Spotlight Of Presidential Campaign Politics

Restrictions on direct-to-consumer advertising of prescription drugs are among health care proposals being offered by 2004 Democratic presidential candidates

FDA Efficacy Standard Is Target Of WLF Suit; “Tiered” Approvals Proposed

FDA should grant "initial" approvals based on evidence of efficacy derived from case histories, the Washington Legal Foundation asserts in a lawsuit seeking creation of a tiered drug approval system

Related Content

UsernamePublicRestriction

Register

PS042106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel